

**CANCER PREVENTION AND RESEARCH  
INSTITUTE OF TEXAS**

**ANNUAL FINANCIAL REPORT**

**For The Year Ended August 31, 2012**



**James M. Mansour**  
Chairman

**William "Bill" Gimson**  
Executive Director



## TABLE OF CONTENTS

Letter of Transmittal .....	1
Exhibit I – Combined Balance Sheet/Statement of Net Assets – Governmental Funds .....	2
Exhibit A-1 – Combining Balance Sheet – All General and Consolidated Funds .....	3
Exhibit B-1 – Combining Balance Sheet – Special Revenue Funds .....	4
Exhibit II – Combined Statement of Revenues, Expenditures, and Changes in Fund Balances/Statement of Activities – Governmental Funds .....	5
Exhibit A-2 – Combining Statement of Revenues, Expenditures, and Changes In Fund Balances – All General and Consolidated Funds .....	6
Exhibit B-2 – Combining Statement of Revenues, Expenditures, and Changes In Fund Balances – Special Revenue Funds .....	7
Notes to the Financial Statements	
List of Notes to Financial Statements for Full Reporting Agencies .....	8
Notes Applicable to Agency .....	9
Schedule 1B – Schedule of State Grant Pass-Throughs From/To State Agencies .....	16



CANCER PREVENTION &  
RESEARCH INSTITUTE OF TEXAS

---

November 20, 2012

Honorable Rick Perry, Governor  
Honorable Susan Combs, Texas Comptroller  
John O'Brien, Director, Legislative Budget Board  
John Keel, CPA, State Auditor

Lady and Gentlemen:

We are pleased to submit the annual financial report of the Cancer Prevention and Research Institute of Texas for the year ended August 31, 2012, in compliance with Texas Government Code Annotated, Section 2101.011, and in accordance with the requirements established by the Comptroller of Public Accounts.

Due to the statewide requirements embedded in Governmental Accounting Standards Board (GASB) Statement No. 34, *Basic Financial Statements – and Management's Discussion and Analysis – for State and Local Governments*, the Comptroller of Public Accounts does not require the accompanying annual financial report to comply with all the requirements in this statement. The financial report will be considered for audit by the State Auditor as part of the audit of the State of Texas *Comprehensive Annual Financial Report (CAFR)*; therefore, an opinion has not been expressed on the financial statements and related information contained in this report.

If you have any questions, please contact Alfonso Royal at (512) 305-8488 or Michelle Huddleston at (512) 305-8420.

Sincerely,

A handwritten signature in blue ink that reads "Heidi McConnell". The signature is written in a cursive style.

Heidi McConnell  
Chief Operating Officer

UNAUDITED

**Cancer Prevention and Research Institute of Texas (542)**  
**Exhibit I - Combined Balance Sheet/Statement of Net Assets - Governmental Funds**  
**August 31, 2012**

	Governmental Fund Types		Governmental Funds Total	Capital Assets Adjustments	Long-Term Liabilities Adjustments	Other Adjustments	Statement of Net Assets
	General Funds (Ex A-1)	Special Funds (Ex B-1)					
<b>ASSETS</b>							
Current Assets:							
Cash (Note 3)							
On Hand	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Cash in State Treasury	284,473.83	934,520.69	1,218,994.52				\$ 1,218,994.52
Legislative Appropriations							\$ -
Receivables from:							
Accounts Receivable							\$ -
Due From Other Agencies	2,017,257.16		2,017,257.16				\$ 2,017,257.16
Interfund Receivables	-		-				\$ -
Consumable Inventories	8,581.49		8,581.49				\$ 8,581.49
Other Current Assets		17,140.00	17,140.00				
Non-Current Assets:							
Capital Assets (Note 2):							
Depreciable:							
Furniture and Equipment				401,124.07			\$ 401,124.07
Less Accumulated Depreciation				(233,297.03)			\$ (233,297.03)
<b>Total Assets</b>	<b>\$ 2,310,312.48</b>	<b>\$ 951,660.69</b>	<b>\$ 3,261,973.17</b>	<b>\$ 167,827.04</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 3,412,660.21</b>
<b>LIABILITIES AND FUND BALANCES</b>							
Liabilities							
Current Liabilities:							
Payables from:							
Accounts	\$ 7,449,922.60	\$ 1,395.23	\$ 7,451,317.83	\$ -	\$ -	\$ -	\$ 7,451,317.83
Payroll	208,969.28	-	208,969.28				\$ 208,969.28
Due to Other Agencies	7,749,491.42	-	7,749,491.42				\$ 7,749,491.42
Interfund Payables	-	-	-				\$ -
Deferred Revenues		226,302.00	226,302.00				
Employees' Compensable Leave (Note 5)		-	-		273,034.86		\$ 273,034.86
Non-Current Liabilities							
Employees' Compensable Leave (Note 5)	-	-	-		161,189.63		\$ 161,189.63
<b>Total Liabilities</b>	<b>\$ 15,408,383.30</b>	<b>\$ 227,697.23</b>	<b>\$ 15,636,080.53</b>	<b>\$ -</b>	<b>\$ 434,224.49</b>	<b>\$ -</b>	<b>\$ 15,844,003.02</b>
<b>Fund Financial Statement</b>							
Fund Balances (Deficits):							
Nonspendable	\$ 8,581.49	\$ -					
Restricted	-	723,963.46	723,963.46				\$ 723,963.46
Committed	284,473.83	-					\$ -
Assigned	-	-					\$ -
Unassigned	(13,391,126.14)	-	(13,391,126.14)				\$ (13,391,126.14)
<b>Total Fund Balances</b>	<b>\$ (13,098,070.82)</b>	<b>\$ 723,963.46</b>	<b>\$ (12,667,162.68)</b>				<b>\$ (12,667,162.68)</b>
<b>Total Liabilities and Fund Balances</b>	<b>\$ 2,310,312.48</b>	<b>\$ 951,660.69</b>	<b>\$ 2,968,917.85</b>				<b>\$ 3,176,840.34</b>
<b>Government-Wide Statement of Net Assets</b>							
Net Assets							
Invested in Capital Assets, net of Related Debt				\$ 167,827.04			\$ 167,827.04
Restricted For							
Debt Retirement							\$ -
Capital Projects							\$ -
Other							\$ -
Funds Held as Permanent Investments:							
Expendable							\$ -
Non-Expendable							\$ -
Other							\$ -
Unrestricted					\$ (434,224.49)		\$ (434,224.49)
<b>Total Net Assets</b>				<b>\$ 167,827.04</b>	<b>\$ (434,224.49)</b>	<b>\$ -</b>	<b>\$ (12,933,560.13)</b>

The accompanying notes to the financial statements are an integral part of this statement.

**UNAUDITED**

**Cancer Prevention and Research Institute of Texas (542)  
Exhibit A-1 - Combining Balance Sheet - All General and Consolidated Funds  
August 31, 2012**

	<u>General</u>	<u>Consolidated Accounts</u>		
	<u>Fund 1</u> <u>(0001)*</u> <u>U/F (0001)</u>	<u>Fund 1</u> <u>(5136)*</u> <u>U/F (5136)</u>	<u>Fund 2</u> <u>(7639)*</u> <u>U/F (7639)</u>	
<b>ASSETS</b>				
Current Assets:				
Cash				
On Hand	\$	\$ -	\$	\$ -
In State Treasury		284,473.83		\$ 284,473.83
Legislative Appropriations				\$ -
				\$ -
Receivables from:				\$ -
Accounts Receivable				\$ -
Due From Other Agencies			\$ 2,017,257.16	\$ 2,017,257.16
Interfund Receivables			\$ -	\$ -
Consumable Inventories			\$ 8,581.49	\$ 8,581.49
<b>Total Assets</b>	<b>\$ -</b>	<b>\$ 284,473.83</b>	<b>\$ 2,025,838.65</b>	<b>\$ 2,310,312.48</b>
<b>LIABILITIES AND FUND BALANCES</b>				
Liabilities				
Current Liabilities:				
Payables from				\$ -
Accounts		\$	\$ 7,449,922.60	\$ 7,449,922.60
Payroll			\$ 208,969.28	\$ 208,969.28
Due To Other Agencies			\$ 7,749,491.42	\$ 7,749,491.42
Interfund Payable			\$ -	\$ -
Employees' Compensable Leave				\$ -
Non-Current Liabilities				\$ -
Employees' Compensable Leave				\$ -
<b>Total Liabilities</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 15,408,383.30</b>	<b>\$ 15,408,383.30</b>
Fund Balances (Deficits):				
Nonspendable			\$ 8,581.49	\$ 8,581.49
Restricted				\$ -
Committed		\$ 284,473.83		\$ 284,473.83
Assigned				\$ -
Unassigned			\$ (13,391,126.14)	\$ (13,391,126.14)
<b>Total Fund Balances</b>	<b>\$ -</b>	<b>\$ 284,473.83</b>	<b>\$ (13,382,544.65)</b>	<b>\$ (13,098,070.82)</b>
<b>Total Liabilities and Fund Balances</b>	<b>\$ -</b>	<b>\$ 284,473.83</b>	<b>\$ 2,025,838.65</b>	<b>\$ 2,310,312.48</b>

\* GAAP Fund is noted as (XXXX), USAS D23 U/F (XXXX)

**UNAUDITED**

**Cancer Prevention and Research Institute of Texas (542)  
Exhibit B-1 - Combining Balance Sheet - Special Revenue Funds  
August 31, 2012**

	<u>Special Revenue</u>	
	<u>Fund 1</u>	
	<u>(2999)*</u>	<u>Total</u>
	<u>U/F (2999)</u>	<u>(Ex I)</u>
<b>ASSETS</b>		
Current Assets:		
Cash		
On Hand	\$ -	\$ -
In State Treasury	934,520.69	934,520.69
Other Current Assets	17,140.00	17,140.00
Total Assets	<u>\$ 951,660.69</u>	<u>\$ 951,660.69</u>
<b>LIABILITIES AND FUND BALANCES</b>		
Liabilities		
Current Liabilities:		
Payables from		
Accounts	\$ 1,395.23	\$ 1,395.23
Deferred Revenues	226,302.00	226,302.00
Total Liabilities	<u>\$ 227,697.23</u>	<u>\$ 227,697.23</u>
Fund Balances (Deficits):		
Nonspendable	\$ -	\$ -
Restricted	\$ 723,963.46	\$ 723,963.46
Committed	\$ -	\$ -
Assigned	\$ -	\$ -
Unassigned	\$ -	\$ -
Total Fund Balances	<u>\$ 723,963.46</u>	<u>\$ 723,963.46</u>
Total Liabilities and Fund Balances	<u>\$ 951,660.69</u>	<u>\$ 951,660.69</u>

\* GAAP Fund is noted as (XXXX), USAS D23 U/F (XXXX)

**UNAUDITED**

**Cancer Prevention and Research Institute of Texas (542)  
Exhibit II - Combined Statement of Revenues, Expenditures and Changes in Fund Balances/Statement of Activities -  
Governmental Funds  
For the Fiscal Year Ended August 31, 2012**

	<b>General Funds</b> (Ex A-2)	<b>Special Revenue Funds</b> (Ex B-2)	<b>Governmental Funds Total</b>	<b>Capital Assets Adjustments</b>	<b>Long-Term Liabilities Adjustments</b>	<b>Other Adjustments</b>	<b>Statement of Activities</b>
<b>REVENUES**</b>							
Legislative Appropriations							
Original Appropriations (GR)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Additional Appropriations (GR)	-	-	-	-	-	-	-
State Grant Pass-Through Revenue (GR)	-	-	-	-	-	-	-
License, Fees & Permits (PR)	76,896.19	260,122.45	337,018.64	-	-	-	337,018.64
Interest and Investment Income (GR)	1,344.76	1,426.00	2,770.76	-	-	-	2,770.76
Sales of Good and Services (PR)	-	-	-	-	-	-	-
Other (GR)	42,628.85	600,064.01	642,692.86	-	-	-	642,692.86
<b>Total Revenues</b>	<b>120,869.80</b>	<b>861,612.46</b>	<b>982,482.26</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>982,482.26</b>
<b>EXPENDITURES</b>							
Salaries and Wages	\$ 2,079,298.62	\$ 390,666.70	\$ 2,469,965.32	\$ -	\$ 434,224.49	\$ -	\$ 2,904,189.81
Payroll Related Costs	370,691.62	-	370,691.62	-	-	-	370,691.62
Professional Fees and Services	11,448,212.34	-	11,448,212.34	-	-	-	11,448,212.34
Travel	63,592.87	-	63,592.87	-	-	-	63,592.87
Materials and Supplies	114,475.22	-	114,475.22	-	-	-	114,475.22
Communication and Utilities	98,868.32	-	98,868.32	-	-	-	98,868.32
Repairs and Maintenance	(5,711.91)	-	(5,711.91)	-	-	-	(5,711.91)
Rentals and Leases	447,284.59	-	447,284.59	-	-	-	447,284.59
Printing and Reproduction	12,917.16	-	12,917.16	-	-	-	12,917.16
State Grant Pass-Through Expenditure	65,459,151.92	-	65,459,151.92	-	-	-	65,459,151.92
Public Assistance Payments	28,463,098.57	-	28,463,098.57	-	-	-	28,463,098.57
Other Expenditures	283,188.59	646,994.30	930,182.89	-	-	-	930,182.89
Capital Outlay	172,609.03	-	172,609.03	(401,124.00)	-	-	(228,514.97)
Depreciation Expense	-	-	-	233,297.03	-	-	233,297.03
<b>Total Expenditures/Expenses</b>	<b>\$ 109,007,676.94</b>	<b>\$ 1,037,661.00</b>	<b>\$ 110,045,337.94</b>	<b>\$ (167,826.97)</b>	<b>\$ 434,224.49</b>	<b>\$ -</b>	<b>\$ 110,311,735.46</b>
Excess (Deficiency) of Revenues over Expenditures	\$ (108,886,807.14)	\$ (176,048.54)	\$ (109,062,855.68)	\$ 167,826.97	\$ (434,224.49)	\$ -	\$ (109,329,253.20)
<b>OTHER FINANCING SOURCES (USES)</b>							
Transfer In	\$ 230,165,554.73	\$ -	\$ 230,165,554.73	\$ -	\$ -	\$ -	\$ 230,165,554.73
Transfer Out	(131,036,219.05)	-	(131,036,219.05)	-	-	-	(131,036,219.05)
Legislative Transfer In	-	-	-	-	-	-	-
Legislative Transfer Out	-	-	-	-	-	-	-
<b>Total Other Financing Sources (Uses)</b>	<b>\$ 99,129,335.68</b>	<b>\$ -</b>	<b>\$ 99,129,335.68</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 99,129,335.68</b>
<b>Net Change in Fund Balances/Net Assets</b>	<b>\$ (9,757,471.46)</b>	<b>\$ (176,048.54)</b>	<b>\$ (9,933,520.00)</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ (10,199,917.52)</b>
<b>Fund Financial Statement - Fund Balances</b>							
Fund Balances, September 1, 2011	\$ (3,340,599.36)	\$ 900,012.00	\$ (3,340,599.36)	\$ -	\$ -	\$ -	\$ (3,340,599.36)
Restatements	-	-	-	-	-	-	-
Fund Balances, September 1, 2011, as Restated	\$ (3,340,599.36)	\$ 900,012.00	\$ (3,340,599.36)	\$ -	\$ -	\$ -	\$ (3,340,599.36)
Appropriations Lapsed	-	-	-	-	-	-	-
Fund Balances, August 31, 2012	\$ (13,098,070.82)	\$ 723,963.46	\$ (13,274,119.36)	\$ -	\$ -	\$ -	\$ (13,540,516.88)
<b>Government-Wide Statement of Net Assets</b>							
Net Assets/Net Change in Net Assets			(13,274,119.36)	167,826.97	(434,224.49)	-	(13,540,516.88)
Net Assets, September 1, 2011					-		
Restatements					-		
Net Assets, September 1, 2011, as Restated					-		
Net Assets, August 31, 2012			(13,274,119.36)	167,826.97	(434,224.49)	-	(13,540,516.88)

\*\* When analyzing which comptroller object code to use, agencies need to determine if it rolls to Program Revenue (PR) or General Revenue (GR) on the Statement of Activities

The accompanying notes to the financial statements are an integral part of this statement.



**UNAUDITED**

**Cancer Prevention and Research Institute of Texas (542)**  
**Exhibit A-2 - Combining Statement of Revenues, Expenditures and Changes in Fund Balances -**  
**All General and Consolidated Funds**  
**For the Fiscal Year Ended August 31, 2012**

	<u>General</u>	<u>Consolidated Accounts</u>		
	<u>Fund 1</u> <u>(0001)*</u> <u>U/F (0001)</u>	<u>Fund 1</u> <u>(5136)*</u> <u>U/F (5136)</u>	<u>Fund 2</u> <u>(7639)*</u> <u>U/F (7639)</u>	
<b>REVENUES**</b>				
Legislative Appropriations				
Original Appropriations (GR)	\$	\$	\$	\$ -
Additional Appropriations (GR)				-
State Grant Pass-Through Revenue (GR)				-
License, Fees & Permits (PR)		76,896.19		76,896.19
Interest and Investment Income (GR)		1,344.76		1,344.76
Sales of Good and Services (PR)		-		-
Other (GR)		41,092.43	1,536.42	42,628.85
Total Revenues	\$ -	\$ 119,333.38	\$ 1,536.42	\$ 120,869.80
<b>EXPENDITURES</b>				
Salaries and Wages	\$		\$ 2,079,298.62	\$ 2,079,298.62
Payroll Related Costs			370,691.62	370,691.62
Professional Fees and Services		30,789.00	11,417,423.34	11,448,212.34
Travel			63,592.87	63,592.87
Materials and Supplies			114,475.22	114,475.22
Communication and Utilities			98,868.32	98,868.32
Repairs and Maintenance			(5,711.91)	(5,711.91)
Rentals and Leases			447,284.59	447,284.59
Printing and Reproduction			12,917.16	12,917.16
State Grant Pass-Through Expenditure			65,459,151.92	65,459,151.92
Public Assistance Payments		(1,399.21)	28,464,497.78	28,463,098.57
Other Expenditures			283,188.59	283,188.59
Capital Outlay			172,609.03	172,609.03
Total Expenditures	\$ -	\$ 29,389.79	\$ 108,978,287.15	\$ 109,007,676.94
Excess (Deficiency) of Revenues over Expenditures	\$ -	\$ 89,943.59	\$ (108,976,750.73)	\$ (108,886,807.14)
<b>OTHER FINANCING SOURCES (USES)</b>				
Transfer In		\$	\$ 230,165,554.73	\$ 230,165,554.73
Transfer Out			(131,036,219.05)	(131,036,219.05)
Legislative Transfer In				-
Legislative Transfer Out				-
Total Other Financing Sources (Uses)	\$ -	\$ -	\$ 99,129,335.68	\$ 99,129,335.68
Net Change in Fund Balances	\$ -	\$ 89,943.59	\$ (9,847,415.05)	\$ (9,757,471.46)
<b>Fund Financial Statement - Fund Balances</b>				
Fund Balances, September 1, 2011		\$ 194,530.24	\$ (3,535,129.60)	\$ (3,340,599.36)
Restatements				-
Fund Balances, September 1, 2011, as Restated	\$ -	\$ 194,530.24	\$ (3,535,129.60)	\$ (3,340,599.36)
Appropriations Lapsed				-
Fund Balances, August 31, 2012	\$ -	\$ 284,473.83	\$ (13,382,544.65)	\$ (13,098,070.82)

\* GAAP Fund is noted as (XXXX), USAS D23 U/F (XXXX)

\*\* When analyzing which comptroller object code to use, agencies need to determine if it rolls to Program Revenue (PR) or General Revenue (GR) on the Statement of Activities

**UNAUDITED**

**Cancer Prevention and Research Institute of Texas (542)  
Exhibit B-2 - Combining Statement of Revenues, Expenditures and Changes in Fund B  
Special Revenue Funds  
For the Fiscal Year Ended August 31, 2012**

	<u>Special Revenue</u>	
	<u>Fund 1</u>	
	<u>(2999)*</u>	<u>Total</u>
	<u>U/F (2999)</u>	<u>(Ex II)</u>
<b>REVENUES**</b>		
Legislative Appropriations		
Original Appropriations (GR)	\$	\$ -
Additional Appropriations (GR)		-
State Grant Pass-Through Revenue (GR)		-
License, Fees & Permits (PR)	260,122.45	260,122.45
Interest and Investment Income (GR)	1,426.00	1,426.00
Sales of Good and Services (PR)		-
Other (GR)	600,064.01	600,064.01
<b>Total Revenues</b>	<b>\$ 861,612.46</b>	<b>\$ 861,612.46</b>
<b>EXPENDITURES</b>		
Salaries and Wages	\$ 390,666.70	\$ 390,666.70
Payroll Related Costs		-
Professional Fees and Services		-
Travel		-
Materials and Supplies		-
Communication and Utilities		-
Repairs and Maintenance		-
Rentals and Leases		-
Printing and Reproduction		-
State Grant Pass-Through Expenditure		-
Public Assistance Payments		-
Other Expenditures	646,994.30	646,994.30
Capital Outlay		-
<b>Total Expenditures</b>	<b>\$ 1,037,661.00</b>	<b>\$ 1,037,661.00</b>
Excess (Deficiency) of Revenues over Expenditures	<b>\$ (176,048.54)</b>	<b>\$ (176,048.54)</b>
<b>OTHER FINANCING SOURCES (USES)</b>		
Transfer In		\$ -
Transfer Out		-
Legislative Transfer In		-
Legislative Transfer Out		-
<b>Total Other Financing Sources (Uses)</b>	<b>\$ -</b>	<b>\$ -</b>
<b>Net Change in Fund Balances</b>	<b>\$ (176,048.54)</b>	<b>\$ (176,048.54)</b>
<b>Fund Financial Statement - Fund Balances</b>		
Fund Balances, September 1, 2011	\$ 900,012.00	\$ 900,012.00
Restatements		-
Fund Balances, September 1, 2011, as Restated	\$ 900,012.00	\$ 900,012.00
Appropriations Lapsed		-
Fund Balances, August 31, 2012	<b>\$ 723,963.46</b>	<b>\$ 723,963.46</b>

\* GAAP Fund is noted as (XXXX), USAS D23 U/F (XXXX)

\*\* When analyzing which comptroller object code to use, agencies need to determine if it rolls to Program Revenue (PR) or General Revenue (GR) on the Statement of Activities

**List of Notes to Financial Statements for Full Reporting Agencies  
(please fill in all blanks and spaces)**

Agency Number: 542  
 Agency Name: Cancer Prevention and Research Institute of Texas

Full Reporting Agencies must complete this list and submit all applicable notes via e-mail to the FRS analyst assigned to the agency by 11/20. Each applicable note should be on a separate page and in Microsoft Word format. Tables should be presented within the Word document and not as a separate Excel or other database application file.

Under the "Submitted" column, place an "X" by the notes that are submitted to the Comptroller's office. Under the "Not Applicable" column, place an "X" by the notes that are not applicable and therefore not submitted.

<b>Note #</b>	<b>Description</b>	<b>Submitted</b>	<b>Not Applicable</b>
1	Summary of Significant Accounting Policies	X	
2	Capital Assets	X	
3	Deposits, Investments and Repurchase Agreements		X
4	Short-Term Debt		X
5	Long-Term Liabilities	X	
6	Bonded Indebtedness		X
7	Capital Leases		X
8	Operating Leases	X	
9	Retirement Plans		X
10	Deferred Compensation		X
11	Postemployment Health Care and Life Insurance Benefits		X
12	Interfund Activity and Transactions		X
13	Continuance Subject to Review		X
14	Adjustments to Fund Balance/Net Assets		X
15	Contingent Liabilities		X
16	Subsequent Events		X
17	Risk Management		X
18	Management Discussion and Analysis		X
19	The Financial Reporting Entity	X	
20	Stewardship, Compliance and Accountability		X
21	Not Applicable to the AFR		X
22	Donor Restricted Endowments		X
23	Extraordinary and Special Items		X
24	Disaggregation of Receivable and Payable Balances		X
25	Termination Benefits		X
26	Segment Information		X

**NOTE 1: Summary of Significant Accounting Policies**

**Entity**

The Cancer Prevention and Research Institute of Texas is an agency of the state of Texas and its financial records comply with state statutes and regulations. This includes compliance with the Texas Comptroller of Public Accounts' *Reporting Requirements for Annual Financial Reports of State Agencies and Universities*.

The Cancer Prevention and Research Institute of Texas is the state agency mandated to (1) create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of cancer and cures for cancer; (2) attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in this state; and (3) develop and implement the Texas Cancer Plan.

Due to the statewide requirements embedded in GASB Statement No. 34, *Basic Financial Statements – and Management's Discussion and Analysis – for State and Local Governments*, the Comptroller of Public Accounts does not require the accompanying annual financial report to comply with all of the requirements in this statement. The financial report will be considered for audit by the State Auditor as part of the audit of the state of Texas *Comprehensive Annual Financial Report*; therefore, an opinion has not been expressed on the financial statements and related information contained in this report.

Blended Component Units

No component units have been identified which should have been blended into an appropriate fund.

**Fund Structure**

The accompanying financial statements are presented on the basis of funds, each of which is considered a separate accounting entity.

**Governmental Fund Types and Government-wide Adjustment Fund Types**

***General Revenue Funds***

Cancer Prevention and Research fund (fund 5136) – This fund is used to receive and account for fees charged for the specialty license plates and is in addition to motor vehicle registration fees. Additionally, the fund receives fees from company applications and is used to receive all miscellaneous agency revenues.

***Capital Project Funds***

The capital projects fund (fund 7639) is used to account for general obligation bond proceeds issued by the Texas Public Finance Authority. The purpose of these bond proceeds is to provide cancer prevention and research grants to Texas institutions and organizations.

***Capital Assets Adjustment Fund Type***

The capital assets adjustment fund (fund 7639) will be used to convert governmental fund types' capital assets from modified accrual to full accrual.

***Long-Term Liabilities Adjustment Fund Type***

The long-term liabilities adjustment fund (fund 9997) will be used to convert governmental fund types' debt from modified accrual to full accrual.

**Basis of Accounting**

The basis of accounting determines when revenues and expenditures or expenses are recognized in the accounts reported in the financial statements. The accounting and financial reporting treatment applied to a fund is determined by its measurement focus.

Governmental fund types that build the fund financial statements are accounted for using the modified accrual basis of accounting. Under the modified accrual basis, revenues are recognized in the period in which they become both measurable and available to finance operations of the fiscal year or liquidate liabilities existing at fiscal year end. The State of Texas considers receivables collected within sixty days after year-end to be available and recognizes them as revenues of the current year for fund financial statements prepared on the modified accrual basis. Expenditures and other uses of financial resources are recognized when the related liability is incurred.

Governmental adjustment fund types that will build the government-wide financial statements are accounted for using the full accrual basis of accounting. This includes capital assets, accumulated depreciation, unpaid employee compensable leave, the unmatured debt service (principal and interest) on general long-term liabilities, long-term capital leases, long-term claims and judgments and full accrual revenues and expenses. The activity will be recognized in these fund types.

**Budget and Budgetary Accounting**

The budget is prepared biennially and represents appropriations authorized by the legislature and approved by the Governor (the General Appropriations Act).

Unencumbered appropriations are generally subject to lapse 60 days after the end of the fiscal year for which they were appropriated.

---

**Assets, Liabilities, and Fund Balances/Net Assets**

---

**Assets**

***Inventories and Prepaid Items***

Inventories include both merchandise inventories on hand for sale and consumable inventories. Inventories are valued at cost, generally using the last-in, first-out method. The consumption method of accounting is used to account for inventories and prepaid items that appear in the governmental and proprietary fund types. The cost of these items is expensed when the items are consumed.

***Capital Assets***

Assets with an initial individual cost of more than \$5,000 and an estimated useful life in excess of one year are capitalized. These assets are capitalized at cost or, if purchased, at appraisal fair value as the date of acquisition. Purchases of assets by governmental funds are reported as expenditures. Depreciation is reported on all "exhaustible" assets. "Inexhaustible" assets, such as works of art and historical treasures, are not depreciated. Assets are depreciated over the estimated useful life of the asset using the straight-line method.

## Liabilities

### ***Accounts Payable***

Accounts payable represents the liability for the value of assets or services received at the balance sheet date for which payment is pending.

### ***Employees' Compensable Leave Balances***

Employees' compensable leave balances represent the liability that becomes "due" upon the occurrence of relevant events such as resignations, retirements, and uses of leave balances by covered employees. Liabilities are reported separately as either current or noncurrent in the statement of net assets. These obligations are normally paid from the same funding source from which each employee's salary or wage compensation was paid.

## Fund Balance/Net Assets

The difference between fund assets and liabilities is "net assets" on the government-wide, proprietary and fiduciary fund statements, and the "fund balance" is the difference between fund assets and liabilities on the governmental fund statements.

### Fund Balance Components

Fund balances for governmental funds are classified as nonspendable, restricted, committed, assigned or unassigned in the fund financial statements.

- Nonspendable fund balance includes amounts not available to be spent because they are either (1) not in spendable form or (2) legally or contractually required to be maintained intact.
- Restricted fund balance includes those resources that have constraints placed on their use through external parties or by law through constitutional provisions.
- Committed fund balance can be used only for specific purposes pursuant to constraints imposed by a formal action of the Texas Legislature, the state's highest level of decision making authority.
- Assigned fund balance includes amounts constrained by the state's intent to be used for specific purposes, but are neither restricted nor committed. Intent is expressed by (1) the Texas Legislature or (2) a body (for example, a budget or finance committee) or official to which the governing body has delegated the authority to assign amounts to be used for specific purposes.
- Unassigned fund balance is the residual classification for the general fund. This classification represents fund balance that was not assigned to other funds and was not restricted, committed or assigned to specific purposes within the general fund.

**NOTE 2: Capital Assets**

A summary of changes in capital assets for the year ended August 31, 2012, is presented below:

	PRIMARY GOVERNMENT							Balance 08/31/12
	Balance 09/01/11	Adjustments	Reclassifications Completed CIP	Reclassifications Inc-Int'agy Trans	Reclassifications Dec-Int'agy Trans	Additions	Deletions	
<b>GOVERNMENTAL ACTIVITIES</b>								
Nondepreciable Assets								
Land and Land Improvements								\$ -
Infrastructure								\$ -
Construction in Progress								\$ -
Other Capital Assets								\$ -
Total Nondepreciable Assets	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Depreciable Assets								
Buildings and Building Improvements								\$ -
Infrastructure								\$ -
Facilities and Other Improvements								\$ -
Furniture and Equipment	\$ 401,124.07							\$ 401,124.07
Vehicle, Boats and Aircraft								\$ -
Other Capital Assets								\$ -
Total Depreciable Assets at Historical Cost	\$ 401,124.07	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 401,124.07
Less Accumulated Depreciation for:								
Buildings and Building Improvements								\$ -
Infrastructure								\$ -
Facilities and Other Improvements								\$ -
Furniture and Equipment	\$ (157,991.23)					\$ (75,305.80)		\$ (233,297.03)
Vehicles, Boats and Aircraft								\$ -
Other Capital Assets								\$ -
Total Accumulated Depreciation	\$ (157,991.23)	\$ -	\$ -	\$ -	\$ -	\$ (75,305.80)	\$ -	\$ (233,297.03)
Depreciable Assets, Net	\$ 243,132.84	\$ -	\$ -	\$ -	\$ -	\$ (75,305.80)	\$ -	\$ 167,827.04
Governmental Activities Capital Assets, Net	\$ 243,132.84	\$ -	\$ -	\$ -	\$ -	\$ (75,305.80)	\$ -	\$ 167,827.04

**NOTE 5: Summary of Long-Term Liabilities**

**Changes in Long-Term Liabilities**

During the year ended August 31, 2012, the following changes occurred in liabilities:

Governmental Activities	Balance 09/01/11	Additions	Reductions	Balance 8/31/12	Amounts Due Within One Year	Amounts Due Thereafter
Notes and Loans Payable	\$	\$	\$	\$	\$	\$
General Obligation B/P						
Revenue Bonds Payable						
Claims and Judgments						
Capital Lease Obligations						
Compensable Leave	\$ 356,657.13	\$ 170,187.63	\$ (92,620.27)	\$ 434,224.49	\$ 273,034.86	\$ 161,189.63
<b>Total Governmental Activities</b>	<b>\$ 356,657.13</b>	<b>\$ 170,187.63</b>	<b>\$ (92,620.27)</b>	<b>\$ 434,224.49</b>	<b>\$ 273,034.86</b>	<b>\$ 161,189.63</b>

**Employees' Compensable Leave**

A state employee is entitled to be paid for all unused vacation time accrued, in the event of the employee's resignation, dismissal, or separation from State employment, provided the employee has had continuous employment with the State for six months. Expenditures for accumulated annual leave balances are recognized in the period paid or taken in governmental fund types. For these fund types, the liability for unpaid benefits is recorded in the Statement of Net Assets. An expense and liability for proprietary fund types are recorded in the proprietary funds as the benefits accrue to employees. No liability is recorded for non-vesting accumulating rights to receive sick pay benefits.



**NOTE 8: Operating Lease Obligations**

Included in the expenditures reported in the financial statements are the following amounts of rent paid or due under operating leases:

<u>Fund Type</u>	<u>Amount</u>
Bond Proceeds - General Obligation Bonds	\$ 372,730

Future minimum lease rental payments under non-cancelable operating leases having an initial term in excess of one year are as follows:

<b>Year Ended August 31, 2012</b>	
2013	\$ 376,185
2014	\$ 376,185
2015	\$ 376,185
<b>Total Minimum Future Lease Rental Payments</b>	<b>\$ 1,128,555</b>

**NOTE 19: *The Financial Reporting Entity***

**The Financial Reporting Entity**

As required by Generally Accepted Accounting Principles, the financial statements present the Cancer Prevention and Research Institute of Texas (CPRIT) and its component units. The component units discussed in this note are included in CPRIT's reporting entity because of the significance of their operational or financial relationships with CPRIT.

**Individual Component Unit Disclosures**

**Blended Component Units.** A five-member board appointed by the Cancer Prevention and Research Institute of Texas (CPRIT) oversight committee governs the Cancer Prevention and Research Institute of Texas Foundation (CPRIT Foundation). Although it is legally separate from CPRIT, the CPRIT Foundation (a tax-exempt 501(c)3 not for profit entity) is reported as if it were part of the primary government because its sole purpose is to augment CPRIT activities in the form of public outreach, marketing, and executive recruitment. The CPRIT Foundation's financial data is reported in the special revenue fund (USAS D22 fund 2999) of the governmental fund type in CPRIT's AFR.

**Cancer Prevention and Research Institute of Texas (542)**  
**Schedule 1B**  
**Schedule of State Grant Pass-Throughs From/To State Agencies**  
**For the Year Ended August 31, 2012**

Pass-through From	Grant ID	Agency Number	Amount
			-
<b>Total Pass-Through from Other Agencies (Exh. II):</b>			<b>-</b>

Pass-through To	Grant ID	Agency Number	Amount
<b>Identification of selective modifiers of crypt stem cells the cells of origin of intestinal cancer</b>	<b>542.0002</b>		
Texas A&M AgriLife Research		556	196,895.80
			<b>196,895.80</b>
<b>Development, Implementation, and Evaluation of a Cancer Genomics Training Program for Texas Health Educators</b>	<b>542.0003</b>		
Texas A&M University		711	152,151.97
			<b>152,151.97</b>
<b>Development of a novel chemogenetic approach to structure/function analysis of human telomerase RNA? a universal anticancer target</b>	<b>542.0004</b>		
Texas A&M AgriLife Research		556	151,943.29
			<b>151,943.29</b>
<b>More Than A Picnic: It's A Family Affair for Lifestyle Change</b>	<b>542.0005</b>		
Texas A&M University		711	163,926.10
			<b>163,926.10</b>
<b>Increasing Breast and Cervical Cancer Screening in Rural and Frontier Texas Communities: A Sustainable Strategy to Increase Screening and Early Detection</b>	<b>542.0012</b>		
Texas A&M AgriLife Extension Service		555	160,299.36
			<b>160,299.36</b>
<b>Integrated Microfluidic Technology for High Throughput Screening of the Metastatic Potential of Tumor Cells</b>	<b>542.0013</b>		
Texas Tech University		733	117,310.00
			<b>117,310.00</b>
<b>A PUBLIC-PRIVATE PARTNERSHIP FOR CANCER PREVENTION IN RURAL COMMUNITIES</b>	<b>542.0014</b>		
Texas Tech University		733	137,571.66
			<b>137,571.66</b>
<b>Implementation of the Clinical Practice Guidelines for Treating Tobacco Use and Dependence in Oncology and Primary Care Settings</b>	<b>542.0015</b>		
Texas Tech University		733	102,888.51

			<b>102,888.51</b>
<b>Validation of a MCL1 Promoter Deletion as a Molecular Marker for Sensitivity to Bcl-2 Inhibitors in Pediatric Acute Lymphoblastic Leukemia</b>	<b>542.0017</b>		
Texas Tech University Health Sciences Center		739	153,887.52
			<b>153,887.52</b>
<b>Molecular mechanisms of novel inhibitors of the multidrug resistance P-glycoprotein</b>	<b>542.0018</b>		
Texas Tech University Health Sciences Center		739	222,002.99
			<b>222,002.99</b>
<b>Access to Breast Care for West Texas - ABC 4 WT</b>	<b>542.0019</b>		
Texas Tech University Health Sciences Center		739	630,566.91
			<b>630,566.91</b>
<b>West Texas Cancer Survivors Network (WTCSN)</b>	<b>542.0020</b>		
Texas Tech University Health Sciences Center		739	162,184.55
			<b>162,184.55</b>
<b>Enhancing the Anti-Neuroblastoma Activity of Fenretinide by Identifying and Targeting Sphingolipid Pathways that Confer Resistance</b>	<b>542.0021</b>		
Texas Tech University Health Sciences Center		739	277,622.46
			<b>277,622.46</b>
<b>Administrative Core</b>	<b>542.0022</b>		
Texas Tech University Health Sciences Center		739	59,240.23
			<b>59,240.23</b>
<b>C1: Biobanking of Cell Lines and Xenografts</b>	<b>542.0023</b>		
Texas Tech University Health Sciences Center		739	258,674.51
			<b>258,674.51</b>
<b>P3: Establishing and Characterizing New Cancer Direct Xenografts</b>	<b>542.0024</b>		
Texas Tech University Health Sciences Center		739	310,761.39
			<b>310,761.39</b>
<b>Multiphoton Laser Scanning Microscope for Cancer Research and Drug Discovery</b>	<b>542.0025</b>		
Texas Tech University Health Sciences Center		739	669,228.05
			<b>669,228.05</b>
<b>Dallas Cancer Disparities Community Coalition: Breast Cancer Prevention Education</b>	<b>542.0027</b>		
University of North Texas Health Science Center at Fort Worth		763	93,390.12
			<b>93,390.12</b>
<b>Culturally sensitive HPV Vaccine Education in Tarrant County</b>	<b>542.0028</b>		
University of North Texas Health Science Center at Fort Worth		763	172,725.29
			<b>172,725.29</b>
<b>Cellular Targets of Salinomycin: Novel Cancer Stem-Cell Specific Drug Studied in Yeast</b>	<b>542.0029</b>		
University of North Texas Health Science Center at Fort Worth		763	49,171.12
			<b>49,171.12</b>
<b>The Rural Texas Physician Cancer Screening Education Program in High-Risk Cancer Cluster Regions</b>	<b>542.0030</b>		

University of North Texas Health Science Center at Fort Worth		763	61,692.46 <b>61,692.46</b>
<b>Biodegradable theranostic nanoparticles for detection and treatment of thyroid cancer</b>	<b>542.0031</b>		
University of Texas at Arlington		714	126,438.39 <b>126,438.39</b>
<b>C2: Live Cell Imaging Core</b>	<b>542.0032</b>		
University of Texas at Arlington		714	90,191.33 <b>90,191.33</b>
<b>Molecular Engineering and Preclinical Evaluation of High Potency Therapeutic Antibodies for the Treatment of Cancer</b>	<b>542.0033</b>		
University of Texas at Austin		721	48,986.28 <b>48,986.28</b>
<b>Bioengineering Cancer Immunotherapy: A Synthetic Injectable Microenvironment for DC Migration, Activation and Antigen priming</b>	<b>542.0034</b>		
University of Texas at Austin		721	438,256.59 <b>438,256.59</b>
<b>Advanced (Pre-IND) Preclinical Development of a Novel, Highly Promising, Human Therapeutic Protein For the Treatment of Hepatocellular Carcinoma</b>	<b>542.0035</b>		
University of Texas at Austin		721	748,083.49 <b>748,083.49</b>
<b>ATM Activation by Oxidative Stress: Characterization and Regulation of Signal Transduction Induced by Reactive Oxygen species</b>	<b>542.0036</b>		
University of Texas at Austin		721	148,152.77 <b>148,152.77</b>
<b>Recruitment of First-Time, Tenure-Track Faculty Members</b>	<b>542.0037</b>		
University of Texas at Austin		721	458,962.48 <b>458,962.48</b>
<b>Research Training Award</b>	<b>542.0038</b>		
University of Texas at Austin		721	883,934.29 <b>883,934.29</b>
<b>Determining the Functional Role of microRNAs in Viral Tumorigenesis.</b>	<b>542.0039</b>		
University of Texas at Austin		721	294,028.11 <b>294,028.11</b>
<b>P4: Characterizing the roles of single-strand DNA-binding proteins and DNA-dependent protein kinase in homologous recombination</b>	<b>542.0040</b>		
University of Texas at Austin		721	218,098.71 <b>218,098.71</b>
<b>P1: New Drug Discovery Program</b>	<b>542.0041</b>		
University of Texas at Austin		721	454,602.07 <b>454,602.07</b>
<b>Recruitment of First-Time, Tenure-Track Faculty Members</b>	<b>542.0042</b>		
University of Texas at Austin		721	226,206.88 <b>226,206.88</b>

<b>Development of small molecules mimicking pro-apoptotic proteins for treating prostate cancer</b>	<b>542.0044</b>		
University of Texas at Dallas		738	451,299.47
			<b>451,299.47</b>
<b>Subcellular trafficking studies of Her2 and anti-Her2 antibodies</b>	<b>542.0045</b>		
University of Texas at Dallas		738	309,558.68
			<b>309,558.68</b>
<b>P3: Defining the behavior of PS and PS-targeting agents at the cellular level</b>	<b>542.0046</b>		
University of Texas at Dallas		738	167,028.28
			<b>167,028.28</b>
<b>P2: Roles of Chaperone/beta-catenin Interactions in Prostate Cancer</b>	<b>542.0047</b>		
University of Texas at El Paso		724	167,153.70
			<b>167,153.70</b>
<b>Protein scaffolds for targeted delivery of toxic iron to cancer cells</b>	<b>542.0048</b>		
University of Texas at San Antonio		743	69,682.24
			<b>69,682.24</b>
<b>Understanding the Connection Between Alternative mRNA 3 End Formation and microRNA Function During Tumorigenesis</b>	<b>542.0049</b>		
University of Texas Health Science Center at Houston		744	61,977.03
			<b>61,977.03</b>
<b>Adipose progenitor cells as a new clinical cancer target</b>	<b>542.0050</b>		
University of Texas Health Science Center at Houston		744	120,950.72
			<b>120,950.72</b>
<b>K-ras Spatiotemporal Dynamics: Novel Therapeutic Targets</b>	<b>542.0051</b>		
University of Texas Health Science Center at Houston		744	695,863.47
			<b>695,863.47</b>
<b>Discovery of Novel Anti-Tumor Therapeutics Targeted at Colon Cancer Stem Cells</b>	<b>542.0052</b>		
University of Texas Health Science Center at Houston		744	376,667.70
			<b>376,667.70</b>
<b>Cancer Communication Interventions to Increase HPV Vaccination among Hispanic Adolescents</b>	<b>542.0053</b>		
University of Texas Health Science Center at Houston		744	354,823.44
			<b>354,823.44</b>
<b>Increasing Breast, Cervical, and Colorectal Cancer Screening and HPV Vaccination among Underserved Texans: A Collaboration with the United Way's 2-1-1 Program</b>	<b>542.0055</b>		
University of Texas Health Science Center at Houston		744	422,977.54
			<b>422,977.54</b>
<b>Texas Breast Cancer Screening, Early Detection and Treatment Program Outcomes Study</b>	<b>542.0056</b>		
University of Texas Health Science Center at Houston		744	76,169.01
			<b>76,169.01</b>
<b>Core 1</b>	<b>542.0058</b>		
University of Texas Health Science Center at Houston		744	99,028.06

			<b>99,028.06</b>
<b>Research Training Award</b>	<b>542.0059</b>		
University of Texas Health Science Center at Houston		744	810,932.12
			<b>810,932.12</b>
<b>Using an Evidence-based Lay Health Worker Program to Increase Breast and Cervical Cancer Screening in Low-Income Hispanic Women in Houston</b>	<b>542.0060</b>		
University of Texas Health Science Center at Houston		744	185,277.68
			<b>185,277.68</b>
<b>Administrative Core</b>	<b>542.0061</b>		
Texas A&M University System Health Science Center		709	376,818.51
University of Texas Health Science Center at Houston		744	105,914.27
			<b>482,732.78</b>
<b>P2: Combinatorial Drug Discovery Program</b>	<b>542.0062</b>		
Texas A&M University System Health Science Center		709	561,387.74
			<b>561,387.74</b>
<b>NIR/Visible/UV FACS for Molecular Medicine</b>	<b>542.0063</b>		
University of Texas Health Science Center at Houston		744	440,484.00
			<b>440,484.00</b>
<b>Recruitment of First-Time, Tenure-Track Faculty Members</b>	<b>542.0064</b>		
University of Texas Health Science Center at San Antonio		745	336,529.31
			<b>336,529.31</b>
<b>Salud San Antonio! - Promoting Breast, Cervical, and Colorectal Cancer Education among Latinas</b>	<b>542.0065</b>		
University of Texas Health Science Center at San Antonio		745	125,231.97
			<b>125,231.97</b>
<b>Administrative and Clinical Data Core [Genetics and Biology of Liver Tumorigenesis in Children]</b>	<b>542.0066</b>		
University of Texas Health Science Center at San Antonio		745	111,959.80
			<b>111,959.80</b>
<b>Bioinformatics and Biostatistics Core [Genetics and Biology of Liver Tumorigenesis in Children]</b>	<b>542.0067</b>		
University of Texas Health Science Center at San Antonio		745	322,347.28
			<b>322,347.28</b>
<b>Project 2</b>	<b>542.0069</b>		
University of Texas Health Science Center at San Antonio		745	135,988.60
			<b>135,988.60</b>
<b>Research Training Award</b>	<b>542.0070</b>		
University of Texas Health Science Center at San Antonio		745	912,802.89
			<b>912,802.89</b>
<b>Mechanical Force-Induced Signaling for Local Estrogen Production in Breast Cancer</b>	<b>542.0071</b>		
University of Texas Health Science Center at San Antonio		745	113,367.51
			<b>113,367.51</b>
<b>Rational combinatorial targeting of PDE4 and associated survival pathways in B-cell malignancies</b>	<b>542.0072</b>		
University of Texas Health Science Center at San Antonio		745	221,880.82
			<b>221,880.82</b>
<b>Role of TMEM127 in the endomembrane system and mTOR signaling</b>	<b>542.0073</b>		

University of Texas Health Science Center at San Antonio	745	268,777.15
		<b>268,777.15</b>
<b>Maximizing Cancer Survivorship: Implementation of an Evidence-Based Exercise Program</b>	<b>542.0074</b>	
University of Texas Health Science Center at San Antonio	745	155,513.81
		<b>155,513.81</b>
<b>A peer education and outreach program to prevent cervical cancer among Latina mothers and daughters living in Texas-Mexico border communities</b>	<b>542.0075</b>	
University of Texas Health Science Center at San Antonio	745	98,527.76
		<b>98,527.76</b>
<b>Cord Blood Natural Killer Cells for Patients with Cancer</b>	<b>542.0079</b>	
University of Texas M.D. Anderson Cancer Center	506	34,850.37
		<b>34,850.37</b>
<b>New treatments for mutant K-Ras: the elephant in the room of cancer therapy.</b>	<b>542.0080</b>	
University of Texas M.D. Anderson Cancer Center	506	4,533.35
		<b>4,533.35</b>
<b>Development of a novel anti-EGFR antibody-protamine recombinant protein for in vivo delivery of small Interfering RNAs for cancer therapy</b>	<b>542.0081</b>	
University of Texas M.D. Anderson Cancer Center	506	75,796.75
		<b>75,796.75</b>
<b>Novel angiogenic factor in ovarian cancer microenvironment</b>	<b>542.0082</b>	
University of Texas M.D. Anderson Cancer Center	506	305,602.17
		<b>305,602.17</b>
<b>Next Generation Genomic Sequence Identification of the 19q Familial Wilms Tumor Predisposition Gene</b>	<b>542.0084</b>	
University of Texas M.D. Anderson Cancer Center	506	6,545.62
		<b>6,545.62</b>
<b>Regulation of Ash2L and MLL oncoproteins by PRMT-mediated methylation in normal cells and acute leukemias</b>	<b>542.0085</b>	
University of Texas M.D. Anderson Cancer Center	506	12,432.11
		<b>12,432.11</b>
<b>Effects from Nicotinic Receptor Variations on Smoking Behaviors and Lung Cancer Risk</b>	<b>542.0086</b>	
University of Texas M.D. Anderson Cancer Center	506	174,292.55
		<b>174,292.55</b>
<b>Translational development of novel lymphoma vaccine therapy</b>	<b>542.0087</b>	
University of Texas M.D. Anderson Cancer Center	506	353,621.65
		<b>353,621.65</b>
<b>A single nucleotide polymorphism in Mdm2 regulates p53 activity</b>	<b>542.0088</b>	
University of Texas M.D. Anderson Cancer Center	506	244,582.46
		<b>244,582.46</b>
<b>Self-Antigen Dependence of Chronic Active B-Cell Receptor Signaling in the Activated B-Cell Type of Diffuse Large B-Cell Lymphoma</b>	<b>542.0089</b>	
University of Texas M.D. Anderson Cancer Center	506	355,026.72
		<b>355,026.72</b>



<b>14-3-3zeta-induced microRNA deregulation in early stage breast cancer progression</b>	<b>542.0090</b>		
University of Texas M.D. Anderson Cancer Center		506	213,905.08
			<b>213,905.08</b>
<b>Mechanisms underlying delayed recurrence of ER positive breast cancer: a critical step in the development of effective biomarkers and therapies</b>	<b>542.0091</b>		
University of Texas M.D. Anderson Cancer Center		506	105,582.14
			<b>105,582.14</b>
<b>Discovery and Validation of Novel Cancer Drug Targets through Synthetic Lethal Screening</b>	<b>542.0092</b>		
University of Texas M.D. Anderson Cancer Center		506	338,948.12
			<b>338,948.12</b>
<b>Antibody-free microfluidic isolation and molecular analysis of circulating cancer cells</b>	<b>542.0093</b>		
University of Texas M.D. Anderson Cancer Center		506	213,462.59
			<b>213,462.59</b>
<b>Prostaglandins and Inflammation in Colorectal Cancer</b>	<b>542.0094</b>		
University of Texas M.D. Anderson Cancer Center		506	452,577.34
			<b>452,577.34</b>
<b>Increasing Primary Care Provider's Competence for Identifying and Managing Persons at Increased Breast Cancer Risk: A Professional Oncology Prevention Program</b>	<b>542.0098</b>		
University of Texas M.D. Anderson Cancer Center		506	64,905.58
			<b>64,905.58</b>
<b>Cancer Screening Education for Nurses in Rural or Medically Underserved Areas of Texas</b>	<b>542.0099</b>		
University of Texas M.D. Anderson Cancer Center		506	149,910.92
			<b>149,910.92</b>
<b>Integrated Professional Oncology Curriculum for Texas Primary Care Providers: Enhancing Care and Quality of Life for Breast, Colon and Prostate Cancer Survivors</b>	<b>542.0100</b>		
University of Texas M.D. Anderson Cancer Center		506	73,513.63
			<b>73,513.63</b>
<b>Improving Cord Blood Expansion and Homing for Patients with Cancer</b>	<b>542.0102</b>		
University of Texas M.D. Anderson Cancer Center		506	167,648.44
			<b>167,648.44</b>
<b>TRIM24: a Dual Regulator of p53 and Estrogen Receptor</b>	<b>542.0103</b>		
University of Texas M.D. Anderson Cancer Center		506	413,454.23
			<b>413,454.23</b>
<b>Quality of Supportive Care of Texans with Cancer [CERCIT: Comparative Effectiveness Research on Cancer in Texas]</b>	<b>542.0105</b>		
University of Texas M.D. Anderson Cancer Center		506	154,651.71
			<b>154,651.71</b>
<b>Fast Imaging Methods for Hyperpolarized Nuclei [Novel MRI and MRS Methods for Imaging Cancer Metabolism]</b>	<b>542.0106</b>		
University of Texas M.D. Anderson Cancer Center		506	15,318.97
			<b>15,318.97</b>
<b>Project 3</b>	<b>542.0107</b>		
University of Texas M.D. Anderson Cancer Center		506	79,699.76

			<b>79,699.76</b>
<b>Core 2</b>	<b>542.0108</b>		
University of Texas M.D. Anderson Cancer Center		506	104,389.46
			<b>104,389.46</b>
<b>Recruitment of First-Time, Tenure-Track Faculty Members</b>	<b>542.0109</b>		
University of Texas M.D. Anderson Cancer Center		506	595,086.85
			<b>595,086.85</b>
<b>Recruitment of Rising Stars</b>	<b>542.0110</b>		
University of Texas M.D. Anderson Cancer Center		506	938,907.05
			<b>938,907.05</b>
<b>Research Training Award</b>	<b>542.0111</b>		
University of Texas M.D. Anderson Cancer Center		506	24,880.86
			<b>24,880.86</b>
<b>Pathways Linking Social Determinants of Smoking Cessation</b>	<b>542.0112</b>		
University of Texas M.D. Anderson Cancer Center		506	114,397.71
			<b>114,397.71</b>
<b>Genetic Analysis of Anticipation in Lynch Syndrome</b>	<b>542.0113</b>		
University of Texas M.D. Anderson Cancer Center		506	374,888.89
			<b>374,888.89</b>
<b>A therapeutic approach for lung cancer chemoprevention</b>	<b>542.0114</b>		
University of Texas M.D. Anderson Cancer Center		506	309,546.26
			<b>309,546.26</b>
<b>Mast Cell Tryptases in Lung Cancer Development and Progression</b>	<b>542.0115</b>		
University of Texas M.D. Anderson Cancer Center		506	305,716.27
			<b>305,716.27</b>
<b>Identification of the MicroRNAs-TRAF6 pathway as a therapeutic target for prostate cancer</b>	<b>542.0116</b>		
University of Texas M.D. Anderson Cancer Center		506	154,789.16
			<b>154,789.16</b>
<b>Role of the Histone Demethylase UTX in Breast Cancer Events</b>	<b>542.0117</b>		
University of Texas M.D. Anderson Cancer Center		506	210,154.91
			<b>210,154.91</b>
<b>Augmenting T cell-based melanoma immunotherapy by targeting oncogenic BRAF</b>	<b>542.0118</b>		
University of Texas M.D. Anderson Cancer Center		506	529,616.23
			<b>529,616.23</b>
<b>Deciphering the mechanisms of EGFR-regulated Warburg effect during tumorigenesis</b>	<b>542.0119</b>		
University of Texas M.D. Anderson Cancer Center		506	249,055.91
			<b>249,055.91</b>
<b>Targeting Dendritic Cells to Block Immunosuppression in Breast Cancer</b>	<b>542.0120</b>		
University of Texas M.D. Anderson Cancer Center		506	199,217.41
			<b>199,217.41</b>

<b>Targeting Leukemia-Stromal Interaction to Overcome Drug Resistance in vivo: Novel mechanism and Development of a New Therapeutic Agent</b>	<b>542.0121</b>		
University of Texas M.D. Anderson Cancer Center		506	191,161.32
			<b>191,161.32</b>
<b>Impact of differentiation status on tumorigenesis</b>	<b>542.0122</b>		
University of Texas M.D. Anderson Cancer Center		506	106,897.01
			<b>106,897.01</b>
<b>Prostate Cancer Bone Metastasis Secretome</b>	<b>542.0123</b>		
University of Texas M.D. Anderson Cancer Center		506	236,263.67
			<b>236,263.67</b>
<b>Application of Multi-modal Professional Education Platform to Facilitate Physician Tobacco Counseling for Smokers</b>	<b>542.0124</b>		
University of Texas M.D. Anderson Cancer Center		506	59,384.93
			<b>59,384.93</b>
<b>PTEN-loss enriched Akt inhibition clinical study in colorectal cancer</b>	<b>542.0125</b>		
University of Texas M.D. Anderson Cancer Center		506	17,294.14
			<b>17,294.14</b>
<b>P2: Determining the roles of SOSS complexes in DNA damage repair and tumor suppression</b>	<b>542.0127</b>		
University of Texas M.D. Anderson Cancer Center		506	129,183.62
			<b>129,183.62</b>
<b>Administrative Core</b>	<b>542.0128</b>		
University of Texas M.D. Anderson Cancer Center		506	14,872.71
			<b>14,872.71</b>
<b>C1: Tissue Culture</b>	<b>542.0129</b>		
University of Texas M.D. Anderson Cancer Center		506	109,705.81
			<b>109,705.81</b>
<b>C2: Mouse Models Core</b>	<b>542.0130</b>		
University of Texas M.D. Anderson Cancer Center		506	21,884.27
			<b>21,884.27</b>
<b>P1: Linking the Epigenome to Breast Cancer Etiology</b>	<b>542.0131</b>		
University of Texas M.D. Anderson Cancer Center		506	161,763.91
			<b>161,763.91</b>
<b>P2: Molecular Mechanisms and Functions of Epigenetic Regulators</b>	<b>542.0132</b>		
University of Texas M.D. Anderson Cancer Center		506	48,909.08
			<b>48,909.08</b>
<b>P1: Identification of Topoisomerase-II beta as the primary target of doxorubicin-induced cardiotoxicity and defining the mechanisms of action</b>	<b>542.0133</b>		
University of Texas M.D. Anderson Cancer Center		506	190,935.99
			<b>190,935.99</b>
<b>P3: Therapeutic Target Discovery Program</b>	<b>542.0134</b>		
University of Texas M.D. Anderson Cancer Center		506	126,474.92
			<b>126,474.92</b>
<b>P3: Adoptive Immunotherapy With NK Cells Expanded Ex Vivo For Treatment Of Acute Myeloid Leukemia</b>	<b>542.0135</b>		
University of Texas M.D. Anderson Cancer Center		506	201,183.45

			<b>201,183.45</b>
<b>P4: Adoptive Cell Therapy Using Expanded Melanoma T cells Programmed Ex Vivo for Improved Efficacy In Vivo</b>	<b>542.0136</b>		
University of Texas M.D. Anderson Cancer Center		506	274,772.63
			<b>274,772.63</b>
<b>C2: Quality Assurance Core</b>	<b>542.0137</b>		
University of Texas M.D. Anderson Cancer Center		506	57,935.58
			<b>57,935.58</b>
<b>P2: Advanced Volumetric Imaging and Adaptive Radiotherapy for Detecting and Correcting for Inter-fractional Changes</b>	<b>542.0138</b>		
University of Texas M.D. Anderson Cancer Center		506	80,534.95
			<b>80,534.95</b>
<b>Recruitment of Rising Stars</b>	<b>542.0144</b>		
University of Texas M.D. Anderson Cancer Center		506	118,860.04
			<b>118,860.04</b>
<b>Data Management Core [CERCIT: Comparative Effectiveness Research on Cancer in Texas]</b>	<b>542.0146</b>		
University of Texas Medical Branch at Galveston		723	224,286.36
			<b>224,286.36</b>
<b>Training Core [CERCIT: Comparative Effectiveness Research on Cancer in Texas]</b>	<b>542.0147</b>		
University of Texas Medical Branch at Galveston		723	186,309.13
			<b>186,309.13</b>
<b>Knowledge Transition Core [CERCIT: Comparative Effectiveness Research on Cancer in Texas]</b>	<b>542.0148</b>		
University of Texas Medical Branch at Galveston		723	76,392.53
			<b>76,392.53</b>
<b>Administrative Core [CERCIT: Comparative Effectiveness Research on Cancer in Texas]</b>	<b>542.0149</b>		
University of Texas Medical Branch at Galveston		723	70,498.55
			<b>70,498.55</b>
<b>Evaluation of Cancer Screening Practices [CERCIT: Comparative Effectiveness Research on Cancer in Texas]</b>	<b>542.0150</b>		
University of Texas Medical Branch at Galveston		723	144,107.29
			<b>144,107.29</b>
<b>Quality of Post Treatment Surveillance for Cancer Patients in Texas [CERCIT: Comparative Effectiveness Research on Cancer in Texas]</b>	<b>542.0151</b>		
University of Texas Medical Branch at Galveston		723	182,049.16
			<b>182,049.16</b>
<b>Project 9</b>	<b>542.0152</b>		
University of Texas Medical Branch at Galveston		723	598.41
			<b>598.41</b>
<b>Recruitment of First-Time, Tenure-Track Faculty Members</b>	<b>542.0153</b>		
University of Texas Health Science Center at Houston		744	376,622.53
			<b>376,622.53</b>
<b>Recruitment of First-Time, Tenure-Track Faculty Members</b>	<b>542.0154</b>		
University of Texas Southwestern Medical Center at Dallas		729	437,707.24

			<b>437,707.24</b>
<b>Can glioblastoma growth be suppressed by targeting glutamine metabolism?</b>	<b>542.0155</b>		
University of Texas Southwestern Medical Center at Dallas		729	36,361.07
			<b>36,361.07</b>
<b>Understanding the Activity of a Potent Anticancer Agent</b>	<b>542.0156</b>		
University of Texas Southwestern Medical Center at Dallas		729	48,225.19
			<b>48,225.19</b>
<b>A molecularly targeted anticancer therapeutic strategy premised upon attack of aberrant Wnt pathway responses</b>	<b>542.0157</b>		
University of Texas Southwestern Medical Center at Dallas		729	570,633.80
			<b>570,633.80</b>
<b>Imaging cancerous tissues with liposomal MRI contrast agents that utilize bioengineered nanovalves</b>	<b>542.0158</b>		
University of Texas Southwestern Medical Center at Dallas		729	400,096.63
			<b>400,096.63</b>
<b>The role of IGFBP2 in acute myeloid leukemia</b>	<b>542.0159</b>		
University of Texas Southwestern Medical Center at Dallas		729	417,140.14
			<b>417,140.14</b>
<b>Photonic Probes for Functional Analysis of microRNAs and mRNAs in Living Cells</b>	<b>542.0160</b>		
University of Texas Southwestern Medical Center at Dallas		729	251,257.35
			<b>251,257.35</b>
<b>Model Systems and Translational Studies of Cervical Cancer Progression</b>	<b>542.0161</b>		
University of Texas Southwestern Medical Center at Dallas		729	194,310.75
			<b>194,310.75</b>
<b>Dissecting the Hippo tumor suppressor pathway in organ size control and stem cell proliferation</b>	<b>542.0162</b>		
University of Texas Southwestern Medical Center at Dallas		729	326,629.01
			<b>326,629.01</b>
<b>TAMU-UT Southwestern Partnership for Cancer Imaging and Spectroscopy at 7 Tesla</b>	<b>542.0163</b>		
University of Texas Southwestern Medical Center at Dallas		729	295,031.62
			<b>295,031.62</b>
<b>Impact of GBM-Specific Oncogenic Events on DNA Repair Pathways: Implications for Therapy</b>	<b>542.0164</b>		
University of Texas Southwestern Medical Center at Dallas		729	272,982.37
			<b>272,982.37</b>
<b>Small-molecule differentiation agent to target glioma stem cells</b>	<b>542.0165</b>		
University of Texas Southwestern Medical Center at Dallas		729	113,535.67
			<b>113,535.67</b>
<b>Suppressing maturation of an oncogenic microRNA with small molecules.</b>	<b>542.0166</b>		
University of Texas Southwestern Medical Center at Dallas		729	133,763.10
			<b>133,763.10</b>
<b>Genetic mouse models of glioma: translational tools for therapeutic development</b>	<b>542.0167</b>		
University of Texas Southwestern Medical Center at Dallas		729	313,312.09
			<b>313,312.09</b>

<b>Osteoclast Regulation of Bone Metastasis of Cancer</b>	<b>542.0168</b>		
University of Texas Southwestern Medical Center at Dallas		729	346,069.68
			<b>346,069.68</b>
<b>Discovery and optimization of natural and artificial ligands regulating Hypoxia Inducible Factor</b>	<b>542.0169</b>		
University of Texas Southwestern Medical Center at Dallas		729	571,483.78
			<b>571,483.78</b>
<b>Relating drug resistance and tumor microenvironment to cancer cell heterogeneity</b>	<b>542.0170</b>		
University of Texas Southwestern Medical Center at Dallas		729	494,150.22
			<b>494,150.22</b>
<b>Mapping Inhibitor Interactions and Conformational Space of the MAP3K TAO2, a New Protein Kinase Cancer Drug Target</b>	<b>542.0171</b>		
University of Texas Southwestern Medical Center at Dallas		729	214,241.98
			<b>214,241.98</b>
<b>Evaluating the therapeutic potential of a potent anti-cancer agent</b>	<b>542.0172</b>		
University of Texas Southwestern Medical Center at Dallas		729	138,876.44
			<b>138,876.44</b>
<b>Breast Screening and PATient Navigation (BSPAN)</b>	<b>542.0175</b>		
University of Texas Southwestern Medical Center at Dallas		729	343,084.28
			<b>343,084.28</b>
<b>Increasing colorectal cancer screening in a safety-net health system with a focus on the uninsured: benefits and costs.</b>	<b>542.0176</b>		
University of Texas Southwestern Medical Center at Dallas		729	262,760.94
			<b>262,760.94</b>
<b>An Intervention Promoting HPV Vaccination in Safety-net Clinics</b>	<b>542.0177</b>		
University of Texas Southwestern Medical Center at Dallas		729	111,574.18
			<b>111,574.18</b>
<b>An Improved Transgenesis Platform for Systematic Screening of Tumor Suppressor Activity in Complete Gene Families in Drosophila</b>	<b>542.0178</b>		
University of Texas Southwestern Medical Center at Dallas		729	250,117.20
			<b>250,117.20</b>
<b>Identification of a Novel Oncogene in Clear-Cell Renal Cell Carcinoma</b>	<b>542.0179</b>		
University of Texas Southwestern Medical Center at Dallas		729	313,461.83
			<b>313,461.83</b>
<b>Core 3</b>	<b>542.0180</b>		
University of Texas Southwestern Medical Center at Dallas		729	20,020.29
			<b>20,020.29</b>
<b>Development of a Mouse Model of Hepatoblastoma [Genetics and Biology of Liver Tumorigenesis in Children]</b>	<b>542.0181</b>		
University of Texas Southwestern Medical Center at Dallas		729	2,694.29
			<b>2,694.29</b>
<b>Hyperpolarized 13C tracers of cancer metabolism [Novel MRI and MRS Methods for Imaging Cancer Metabolism]</b>	<b>542.0182</b>		
University of Texas Southwestern Medical Center at Dallas		729	18,622.34

			<b>18,622.34</b>
<b>Biomarkers and Metabolic Pathways in Gliomas [Novel MRI and MRS Methods for Imaging Cancer Metabolism]</b>	<b>542.0183</b>		
University of Texas Southwestern Medical Center at Dallas		729	57,109.92
			<b>57,109.92</b>
<b>Metabolic Imaging of Hyperpolarized 13C Substrates in Animal Models of Cancer [Novel MRI and MRS Methods for Imaging Cancer Metabolism]</b>	<b>542.0184</b>		
University of Texas Southwestern Medical Center at Dallas		729	137,982.71
			<b>137,982.71</b>
<b>High field MRS and CEST imaging of brain tumors: Biomarkers of therapeutic response [Novel MRI and MRS Methods for Imaging Cancer Metabolism]</b>	<b>542.0185</b>		
University of Texas Southwestern Medical Center at Dallas		729	172,443.12
			<b>172,443.12</b>
<b>Development of nuclear receptor and coregulator profiles for diagnostic and therapeutic (theragnostic) targeting of breast and lung cancers</b>	<b>542.0186</b>		
University of Texas Southwestern Medical Center at Dallas		729	44,784.11
			<b>44,784.11</b>
<b>Project 5</b>	<b>542.0187</b>		
University of Texas Southwestern Medical Center at Dallas		729	646,435.60
			<b>646,435.60</b>
<b>Project 6</b>	<b>542.0188</b>		
University of Texas Southwestern Medical Center at Dallas		729	211,738.99
			<b>211,738.99</b>
<b>Recruitment of Rising Stars</b>	<b>542.0190</b>		
University of Texas Southwestern Medical Center at Dallas		729	755,174.69
			<b>755,174.69</b>
<b>Research Training Award</b>	<b>542.0191</b>		
University of Texas Southwestern Medical Center at Dallas		729	969,445.57
			<b>969,445.57</b>
<b>Inhibiting miR-451 as a novel treatment modality for polycythemia, a pre-leukemic disease</b>	<b>542.0192</b>		
University of Texas Southwestern Medical Center at Dallas		729	66,939.60
			<b>66,939.60</b>
<b>A novel strategy for attacking tumors based on the identification of a fundamental carbon-source signal driving cell growth</b>	<b>542.0193</b>		
University of Texas Southwestern Medical Center at Dallas		729	145,533.41
			<b>145,533.41</b>
<b>Bacterial Antitermination Elements as Synthetic Tools that Improve Production of Anticancer Compounds</b>	<b>542.0194</b>		
University of Texas Southwestern Medical Center at Dallas		729	105,402.12
			<b>105,402.12</b>
<b>A genetic approach to target EWS-FLI1 oncoprotein in Ewing's Sarcoma</b>	<b>542.0195</b>		
University of Texas Southwestern Medical Center at Dallas		729	111,859.32
			<b>111,859.32</b>
<b>Unraveling the Molecular Mechanisms and Biomechanics of Glioblastoma Invasion</b>	<b>542.0196</b>		
University of Texas Southwestern Medical Center at Dallas		729	339,073.29

			<b>339,073.29</b>
<b>Targeting HER2 for cancer therapy</b>	<b>542.0197</b>		
University of Texas Southwestern Medical Center at Dallas		729	328,952.30
			<b>328,952.30</b>
<b>Deconstructing oncogenic activity of p53 mutations</b>	<b>542.0198</b>		
University of Texas Southwestern Medical Center at Dallas		729	274,593.23
			<b>274,593.23</b>
<b>Role of ST6GALNAC5's sialoside products in breast cancer metastasis to the brain</b>	<b>542.0199</b>		
University of Texas Southwestern Medical Center at Dallas		729	146,549.13
			<b>146,549.13</b>
<b>Posttranscriptional regulation of noncoding RNAs involved in epigenetic regulation of gene expression</b>	<b>542.0200</b>		
University of Texas Southwestern Medical Center at Dallas		729	89,504.95
			<b>89,504.95</b>
<b>Personalized Online Adaptive Radiation Therapy</b>	<b>542.0201</b>		
University of Texas Southwestern Medical Center at Dallas		729	196,204.24
			<b>196,204.24</b>
<b>Dependence of small cell lung cancer on the basic helix-loop-helix transcription factors Ascl1 and NeuroD1</b>	<b>542.0202</b>		
University of Texas Southwestern Medical Center at Dallas		729	454,023.68
			<b>454,023.68</b>
<b>Identification of Novel Targets for Therapy of Pediatric Germ Cell Tumors</b>	<b>542.0203</b>		
University of Texas Southwestern Medical Center at Dallas		729	253,759.90
			<b>253,759.90</b>
<b>Lumen formation during blood vessel angiogenesis</b>	<b>542.0204</b>		
University of Texas Southwestern Medical Center at Dallas		729	239,450.91
			<b>239,450.91</b>
<b>Biochemical Mechanisms of NF-kappaB Regulation in Cancer Cells</b>	<b>542.0205</b>		
University of Texas Southwestern Medical Center at Dallas		729	212,797.48
			<b>212,797.48</b>
<b>Fort Worth Program for Community Survivorship (ProComS)</b>	<b>542.0207</b>		
University of Texas Southwestern Medical Center at Dallas		729	9,924.46
			<b>9,924.46</b>
<b>Administrative Core</b>	<b>542.0209</b>		
University of Texas Southwestern Medical Center at Dallas		729	19,860.11
			<b>19,860.11</b>
<b>C1: In vivo Imaging Core</b>	<b>542.0210</b>		
University of Texas Southwestern Medical Center at Dallas		729	89,446.22
			<b>89,446.22</b>
<b>P1: Engineering antibodies and antibody fusion proteins that target PS to produce new generation therapeutics</b>	<b>542.0211</b>		
University of Texas Southwestern Medical Center at Dallas		729	209,727.10
			<b>209,727.10</b>
<b>P2: Analysis of the determinants of anti-tumor activity of the engineered antibodies and antibody fusions in mouse models</b>	<b>542.0212</b>		
University of Texas Southwestern Medical Center at Dallas		729	336,939.40



			<b>336,939.40</b>
<b>P1: Impact of DNA-PKcs phosphorylation at T2609 cluster on pathway choice for DNA double-strand break repair and tumorigenesis</b>	<b>542.0214</b>		
University of Texas Southwestern Medical Center at Dallas		729	255,686.54
			<b>255,686.54</b>
<b>P3: Regulation of DNA repair pathway choice by cohesin and the Smc5/6 complex</b>	<b>542.0215</b>		
University of Texas Southwestern Medical Center at Dallas		729	297,445.33
			<b>297,445.33</b>
<b>P2: MicroRNA mechanisms and therapies to protect the heart during cancer chemotherapy</b>	<b>542.0217</b>		
University of Texas Southwestern Medical Center at Dallas		729	216,586.89
			<b>216,586.89</b>
<b>P3: Maladaptive cardiomyocyte autophagy as a mechanism of doxorubicin-induced heart failure</b>	<b>542.0218</b>		
University of Texas Southwestern Medical Center at Dallas		729	259,061.44
			<b>259,061.44</b>
<b>P5: The Coronary Microvasculature as a Target for Cardioprotection for Cancer-Therapy Induced Heart Failure</b>	<b>542.0219</b>		
University of Texas Southwestern Medical Center at Dallas		729	220,403.52
			<b>220,403.52</b>
<b>C1: Biostatistics</b>	<b>542.0221</b>		
University of Texas Southwestern Medical Center at Dallas		729	58,219.53
			<b>58,219.53</b>
<b>P1: Realizing Technological Advances: The State of Texas Advanced Radiation Therapy (START) Trials</b>	<b>542.0222</b>		
University of Texas Southwestern Medical Center at Dallas		729	49,087.86
			<b>49,087.86</b>
<b>P3: Mapping the Landscape of Conditional Vulnerabilities in Ovarian Cancer</b>	<b>542.0223</b>		
University of Texas Southwestern Medical Center at Dallas		729	216,507.71
			<b>216,507.71</b>
<b>C2: HTS Core</b>	<b>542.0225</b>		
University of Texas Southwestern Medical Center at Dallas		729	470,413.69
			<b>470,413.69</b>
<b>C3: Pharmacology Core</b>	<b>542.0226</b>		
University of Texas Southwestern Medical Center at Dallas		729	358,269.18
			<b>358,269.18</b>
<b>P1: Molecular Biomarker ID</b>	<b>542.0227</b>		
University of Texas Southwestern Medical Center at Dallas		729	333,622.30
			<b>333,622.30</b>
<b>P2: Compound Target ID</b>	<b>542.0228</b>		
University of Texas Southwestern Medical Center at Dallas		729	421,968.36
			<b>421,968.36</b>
<b>P3: Chemistry</b>	<b>542.0229</b>		
University of Texas Southwestern Medical Center at Dallas		729	242,844.51
			<b>242,844.51</b>
<b>P1: Establishing New Validated Cancer Cell Lines In Vitro</b>	<b>542.0230</b>		

University of Texas Southwestern Medical Center at Dallas	729	245,896.85	<b>245,896.85</b>
<b>Recruitment of Missing Links</b>	<b>542.0231</b>		
University of Texas Southwestern Medical Center at Dallas	729	544,870.72	<b>544,870.72</b>
<b>Acquisition of a Biomedical Cyclotron and Development of a Comprehensive Positron Emission Tomography Program at UT Southwestern for Cancer Research</b>	<b>542.0232</b>		
University of Texas Southwestern Medical Center at Dallas	729	81,727.01	<b>81,727.01</b>
<b>Framing Effective Cervical Cancer Messages for Vietnamese American Women</b>	<b>542.0237</b>		
University of Houston	730	102,279.99	<b>102,279.99</b>
<b>Research Training Award</b>	<b>542.0238</b>		
University of Houston	730	731,776.87	<b>731,776.87</b>
<b>siRNA/microRNA-conjugated gold nanoparticle dendrons for sensitizing cancer cells to chemotherapy</b>	<b>542.0239</b>		
University of Houston	730	59,595.28	<b>59,595.28</b>
<b>Ultra-Sensitive Multiplex Detection of Lung Cancer Biomarkers Using Immuno-Magnetic Particles</b>	<b>542.0240</b>		
University of Houston	730	163,834.82	<b>163,834.82</b>
<b>Administrative Core</b>	<b>542.0241</b>		
University of Houston	730	82,410.73	<b>82,410.73</b>
<b>C1: Animal Resources Core</b>	<b>542.0242</b>		
University of Houston	730	185,846.01	<b>185,846.01</b>
<b>P1: Roles of Alternate Nuclear Receptors at key steps in Prostate Cancer Progression</b>	<b>542.0243</b>		
University of Houston	730	209,217.14	<b>209,217.14</b>
<b>Prostate Cancer Model in Zebrafish</b>	<b>542.0244</b>		
University of North Texas	752	79,236.94	<b>79,236.94</b>
<b>RP110609 - Targeting the CXCR4 chemokine receptor: a new approach to overcome stromal cell-mediated drug resistance in Acute Lymphoblastic Leukemia (ALL)</b>	<b>542.0245</b>		
University of Texas M.D. Anderson Cancer Center	506	100,043.79	<b>100,043.79</b>
<b>PP110171 - Use of an Automated EMR System to Link Underserved Smokers with Cessation Treatment</b>	<b>542.0246</b>		
University of Texas M.D. Anderson Cancer Center	506	137,377.18	<b>137,377.18</b>
<b>PP110172 - Nurse and Social Worker Training - Access to Cancer Care for Low-Income and Uninsured Patients</b>	<b>542.0247</b>		
University of Texas M.D. Anderson Cancer Center	506	65,836.91	<b>65,836.91</b>

<b>RP120108 - Improving on Anti-CTLA-4 Therapy</b> University of Texas M.D. Anderson Cancer Center	<b>542.0257</b>	506	99,132.80 <b>99,132.80</b>
<b>RP120124 - Investigating the roles of p63 in miRNA regulation in EMT and metastatic breast cancer</b> University of Texas M.D. Anderson Cancer Center	<b>542.0258</b>	506	141,312.86 <b>141,312.86</b>
<b>RP120214 - Clinical Translation of Therapeutic siRNA in Solid Malignancies</b> University of Texas M.D. Anderson Cancer Center	<b>542.0259</b>	506	2,171.28 <b>2,171.28</b>
<b>RP120217 - Role of IL-17 family cytokines in colon inflammation and cancer</b> University of Texas M.D. Anderson Cancer Center	<b>542.0260</b>	506	24,990.27 <b>24,990.27</b>
<b>RP120258 - Towards Personalized Cancer Therapy: Stratification of Oral and Pharyngeal Cancer Based on p53 Mutational Status</b> University of Texas M.D. Anderson Cancer Center	<b>542.0263</b>	506	69,861.73 <b>69,861.73</b>
<b>RP120262 - Functional and structural characterization of small chemical compounds that arrest glioma stem cell growth with high activity and specificity</b> University of Texas Southwestern Medical Center at Dallas	<b>542.0264</b>	729	206,634.81 <b>206,634.81</b>
<b>RP120280 - Chemoprevention of Colon Cancer by Targeting APC-deficient Cells for Apoptosis</b> University of Texas M.D. Anderson Cancer Center	<b>542.0265</b>	506	54,950.26 <b>54,950.26</b>
<b>RP120316 - CBM complex-mediated signaling pathways as potential therapeutic targets for EGFR-induced cancer</b> University of Texas M.D. Anderson Cancer Center	<b>542.0266</b>	506	67,907.29 <b>67,907.29</b>
<b>RP120326 - In-Situ PET Imaging for Adaptive Proton Therapy</b> University of Texas M.D. Anderson Cancer Center	<b>542.0267</b>	506	51,860.71 <b>51,860.71</b>
<b>RP120348 - The University of Texas MD Anderson Cancer Center Science Park Next-Generation Sequencing Facility</b> University of Texas M.D. Anderson Cancer Center	<b>542.0268</b>	506	48,496.66 <b>48,496.66</b>
<b>RP120380 - Distinct microRNAs Regulate Prostate Cancer Stem Cells</b> University of Texas M.D. Anderson Cancer Center	<b>542.0269</b>	506	55,527.51 <b>55,527.51</b>
<b>RP120394 - Molecular Oncogenesis of NANOG in Castration-Resistant Prostate Cancer</b> University of Texas M.D. Anderson Cancer Center	<b>542.0271</b>	506	10,857.55 <b>10,857.55</b>
<b>RP120451 - Novel Strategy for Treatment of HER2-Positive Breast Cancer</b>	<b>542.0273</b>		

University of Texas M.D. Anderson Cancer Center	506	92,916.02	<b>92,916.02</b>
<b>PP120099 - Increasing Breast and Cervical Cancer Screening and Diagnostic Services in 49 Rural, Frontier, and Border Counties: A Strategy to Improve Early Detection</b>	<b>542.0286</b>		
Texas A&M AgriLife Extension Service	555	116,108.99	<b>116,108.99</b>
<b>PP110176 - Enhanced Colorectal Cancer Screening in a Family Medicine Residency Program Serving Low-Income &amp; Underserved: Translating Research Into Practice</b>	<b>542.0287</b>		
Texas A&M University System Health Science Center	709	672,806.31	<b>672,806.31</b>
<b>PP110241 - EPICO: Education to Promote Improved Cancer Outcomes</b>	<b>542.0288</b>		
Texas A&M University System Health Science Center	709	194,961.00	<b>194,961.00</b>
<b>RP120855 - P1: Targeting Cellular Energetics Pathways in Endometrial Cancer</b>	<b>542.0289</b>		
Texas A&M University System Health Science Center	709	3,029.79	<b>3,029.79</b>
<b>RP120429 - A Lentivirus-Mediated Dual Library, Dual Selection Approach for the Identification of Surface Biomarkers and Antibodies Specific to Cancer Cells</b>	<b>542.0291</b>		
Texas A&M Engineering Experiment Station	712	76,855.95	<b>76,855.95</b>
<b>RP121002 - Examination of the Pharmacological Properties of a Novel Antifungal Named Occidiofungin</b>	<b>542.0292</b>		
Texas A&M University	711	49,643.79	<b>49,643.79</b>
<b>RP120052 - Super-high resolution imaging of tumor angiogenesis in deep tissue</b>	<b>542.0293</b>		
University of Texas at Arlington	714	174,623.89	<b>174,623.89</b>
<b>RP120572 - Development of cancer traps for prolonging lifespan by eliminating metastatic cancer cells</b>	<b>542.0294</b>		
University of Texas at Arlington	714	25,698.99	<b>25,698.99</b>
<b>R1116 - Recruitment of First-Time, Tenure-Track Faculty Members</b>	<b>542.0296</b>		
University of Texas at Austin	721	511,756.03	<b>511,756.03</b>
<b>R1118 - Recruitment of First-Time, Tenure-Track Faculty Members</b>	<b>542.0297</b>		
University of Texas at Austin	721	375,469.13	<b>375,469.13</b>
<b>R1120 - Recruitment of First-Time, Tenure-Track Faculty Members</b>	<b>542.0298</b>		
University of Texas at Austin	721	33,317.66	<b>33,317.66</b>
<b>R1202 - Recruitment of First-Time, Tenure-Track Faculty Members</b>	<b>542.0299</b>		

University of Texas at Austin	721	111,336.66	<b>111,336.66</b>
<b>RP110782 - LTQ Orbitrap Velos Mass Spectrometer to Support Cancer Research</b>	<b>542.0302</b>		
University of Texas at Austin	721	980,425.16	<b>980,425.16</b>
<b>RP120194 - Defining and Subverting Allele-Specific Regulatory Networks in Cancer</b>	<b>542.0303</b>		
University of Texas at Austin	721	97,714.19	<b>97,714.19</b>
<b>RP120314 - Engineering and Preliminary Evaluation of a Fully Human, Non-Immunogenic Asparaginase For the Treatment of L-Asn Auxotrophic Cancers</b>	<b>542.0304</b>		
University of Texas at Austin	721	54,041.69	<b>54,041.69</b>
<b>RP120343 - Gli Transcriptional Activity in Basal Cell Carcinomas</b>	<b>542.0305</b>		
University of Texas at Austin	721	172,013.75	<b>172,013.75</b>
<b>RP120393 - Preclinical Development of Texaphyrin-Platinum Conjugates</b>	<b>542.0306</b>		
University of Texas at Austin	721	113,799.36	<b>113,799.36</b>
<b>RP120406 - A New Role for Triptan Drugs in the Treatment of Breast Cancer</b>	<b>542.0307</b>		
University of Texas at Austin	721	114,829.57	<b>114,829.57</b>
<b>RP120459 - Contribution of the BRIGHT transcription factor to autoimmune Diffuse Large B-cell Lymphoma</b>	<b>542.0308</b>		
University of Texas at Austin	721	110,907.91	<b>110,907.91</b>
<b>RP120507 - Massively Parallel Protein Identification for Cancer Biomarker Discovery</b>	<b>542.0309</b>		
University of Texas at Austin	721	53,719.13	<b>53,719.13</b>
<b>R1122 - Recruitment of Missing Links</b>	<b>542.0311</b>		
University of Texas Medical Branch at Galveston	723	1,308,565.83	<b>1,308,565.83</b>
<b>RP120611 - Small Animal Cancer Imaging Core</b>	<b>542.0312</b>		
University of Texas Medical Branch at Galveston	723	368,716.70	<b>368,716.70</b>
<b>PP110220 - Cancer Genetics Services for Rural and Underserved Populations in Texas</b>	<b>542.0313</b>		
University of Texas Southwestern Medical Center at Dallas	729	356,780.39	<b>356,780.39</b>
<b>PP120097 - Breast Screening and Patient Navigation 2 (BSPAN2)</b>	<b>542.0314</b>		
University of Texas Southwestern Medical Center at Dallas	729	25,044.84	<b>25,044.84</b>
<b>R1101 - Recruitment of First-Time, Tenure-Track Faculty Members</b>	<b>542.0316</b>		
University of Texas Southwestern Medical Center at Dallas	729	399,693.42	

			<b>399,693.42</b>
<b>R1103 - Recruitment of First-Time, Tenure-Track Faculty Members</b>	<b>542.0317</b>		
University of Texas Southwestern Medical Center at Dallas		729	894,468.07
			<b>894,468.07</b>
<b>R1109 - Recruitment of Established Investigators</b>	<b>542.0318</b>		
University of Texas Southwestern Medical Center at Dallas		729	1,992,541.01
			<b>1,992,541.01</b>
<b>R1115 - Recruitment of First-Time, Tenure-Track Faculty Members</b>	<b>542.0319</b>		
University of Texas Southwestern Medical Center at Dallas		729	268,265.11
			<b>268,265.11</b>
<b>R1117 - Recruitment of First-Time, Tenure-Track Faculty Members</b>	<b>542.0320</b>		
University of Texas Southwestern Medical Center at Dallas		729	486,613.42
			<b>486,613.42</b>
<b>R1119 - Recruitment of First-Time, Tenure-Track Faculty Members</b>	<b>542.0321</b>		
University of Texas Southwestern Medical Center at Dallas		729	316,935.01
			<b>316,935.01</b>
<b>R1121 - Recruitment of Missing Links</b>	<b>542.0322</b>		
University of Texas Southwestern Medical Center at Dallas		729	730,074.48
			<b>730,074.48</b>
<b>R1207 - Recruitment of First-Time, Tenure-Track Faculty Members</b>	<b>542.0323</b>		
University of Texas Southwestern Medical Center at Dallas		729	181,890.19
			<b>181,890.19</b>
<b>R1208 - Recruitment of First-Time, Tenure-Track Faculty Members</b>	<b>542.0324</b>		
University of Texas Southwestern Medical Center at Dallas		729	2,569.88
			<b>2,569.88</b>
<b>R12HZ - Recruitment of First-Time, Tenure-Track Faculty Members</b>	<b>542.0327</b>		
University of Texas Southwestern Medical Center at Dallas		729	4,302.20
			<b>4,302.20</b>
<b>RP110465-AC - Administrative Core</b>	<b>542.0333</b>		
University of Texas Southwestern Medical Center at Dallas		729	77,476.52
			<b>77,476.52</b>
<b>RP110486-AC - Administrative Core</b>	<b>542.0334</b>		
University of Texas Southwestern Medical Center at Dallas		729	63,382.69
			<b>63,382.69</b>
<b>RP110562-AC - Administrative Core</b>	<b>542.0335</b>		
University of Texas Southwestern Medical Center at Dallas		729	101,819.69
			<b>101,819.69</b>
<b>RP110708-AC - Administrative Core</b>	<b>542.0336</b>		
University of Texas Southwestern Medical Center at Dallas		729	142,617.42
			<b>142,617.42</b>
<b>RP120016 - Small molecule inhibitors of proteasome assembly: a new strategy for cancer therapy</b>	<b>542.0337</b>		
University of Texas Southwestern Medical Center at Dallas		729	46,675.94

			<b>46,675.94</b>
<b>RP120093 - Protein Palmitoyltransferases as Novel Therapeutic Targets for Acquired Lung Cancer Vulnerabilities</b>	<b>542.0338</b>		
University of Texas Southwestern Medical Center at Dallas	729	44,491.33	<b>44,491.33</b>
<b>RP120094 - Turn ON the Tumor Contrast for Surgical Resection of Head and Neck Cancers</b>	<b>542.0339</b>		
University of Texas Southwestern Medical Center at Dallas	729	125,422.11	<b>125,422.11</b>
<b>RP120307 - Factors Influencing Telomerase Action (Assembly, Modification, Recruitment, Activation): Potential Targets for Telomerase Inhibition Cancer Therapy</b>	<b>542.0340</b>		
University of Texas Southwestern Medical Center at Dallas	729	91,943.03	<b>91,943.03</b>
<b>RP120311 - Regulation of Cyclooxygenase-2 (COX-2) Gene Expression by Noncoding RNAs in Cancer</b>	<b>542.0341</b>		
University of Texas Southwestern Medical Center at Dallas	729	101,486.35	<b>101,486.35</b>
<b>RP120340 - Arginine Methylation Link to HPV-16-Induced Cervical Cancer</b>	<b>542.0342</b>		
University of Texas Southwestern Medical Center at Dallas	729	63,832.71	<b>63,832.71</b>
<b>RP120352 - Mechanisms of CRM1-mediated nuclear export in cancer</b>	<b>542.0343</b>		
University of Texas Southwestern Medical Center at Dallas	729	99,391.91	<b>99,391.91</b>
<b>RP120474 - Enabling the structure determination of functional human telomerase holoenzyme</b>	<b>542.0344</b>		
University of Texas Southwestern Medical Center at Dallas	729	62,788.57	<b>62,788.57</b>
<b>RP120613 - Develop cutting-edge proteomics core facility based on high resolution, high accuracy mass spectrometry and high throughput, web-based bioinformatics technology</b>	<b>542.0345</b>		
University of Texas Southwestern Medical Center at Dallas	729	476,451.36	<b>476,451.36</b>
<b>RP120840 - P1: Enhancing the Identification of Markers and Potential Therapeutic Targets for Improving Tumor Response via MIRNA and DNA Methylation Analysis</b>	<b>542.0376</b>		
University of Texas Southwestern Medical Center at Dallas	729	13,441.98	<b>13,441.98</b>
<b>RP120897 - <math>\beta</math>-Lapachone Nanotherapeutics for NQO1-Targeted Therapy of Cancer</b>	<b>542.0377</b>		
University of Texas Southwestern Medical Center at Dallas	729	18,503.98	<b>18,503.98</b>
<b>RP120617 - Advanced in vivo imaging of tumor initiation and progression</b>	<b>542.0380</b>		
University of Houston	730	502,587.65	<b>502,587.65</b>
<b>RP120053 - Beam-Scanning Radar for Tumor Tracking in Lung Cancer Radiotherapy</b>	<b>542.0382</b>		
Texas Tech University	733	37,726.73	

			<b>37,726.73</b>
<b>PP120108 - Access to Breast Care for West Texas - Concho Valley (ABC4WT-CV)</b>	<b>542.0383</b>		
Angelo State University		737	58,366.99
			<b>58,366.99</b>
<b>RP120588 - Targeting the Acidic Tumor Microenvironment with Renal Clearable and pH Responsive Luminescent Gold Nanoparticles</b>	<b>542.0384</b>		
University of Texas at Dallas		738	142,472.31
			<b>142,472.31</b>
<b>PP110156 - ACCION: Against Colorectal Cancer in our Neighborhoods</b>	<b>542.0386</b>		
Texas Tech University Health Sciences Center		739	263,449.76
			<b>263,449.76</b>
<b>RP120168 - Identification of Rheb and Notch-dependent Pathways in Tuberous Sclerosis Complex</b>	<b>542.0388</b>		
Texas Tech University Health Sciences Center		739	42,390.67
			<b>42,390.67</b>
<b>RP120489 - Transporter-Targeted Drug Delivery and Treatment of Brain Metastases of Breast Cancer</b>	<b>542.0389</b>		
Texas Tech University Health Sciences Center		739	63,688.13
			<b>63,688.13</b>
<b>RP120495 - North Texas Clinical Pharmacology Cancer Core</b>	<b>542.0390</b>		
Texas Tech University Health Sciences Center		739	1,121,782.11
			<b>1,121,782.11</b>
<b>RP120528 - Establishing a Cancer Clinical Research Core facility at Texas Tech University Health Science Center in El Paso</b>	<b>542.0391</b>		
Texas Tech University Health Sciences Center		739	50,942.21
			<b>50,942.21</b>
<b>RP120558 - Development of a Novel High-resolution Photoacoustic Microscopy System for Noninvasive in vivo Imaging of Melanoma</b>	<b>542.0393</b>		
University of Texas at San Antonio		743	25,056.74
			<b>25,056.74</b>
<b>PP110163 - Tu Salud ¡Si Cuenta!: Promotora Training and Community Education for Cancer Prevention</b>	<b>542.0394</b>		
University of Texas Health Science Center at Houston		744	169,477.33
			<b>169,477.33</b>
<b>PP120086 - Increasing Breast, Cervical, and Colon Cancer Screening and increasing HPV vaccination among Underserved Texans: A collaboration with the United Way's 211 Program</b>	<b>542.0395</b>		
University of Texas Health Science Center at Houston		744	29,065.59
			<b>29,065.59</b>
<b>PP110187 - Y Living: A healthy lifestyle program for cancer prevention and risk reduction</b>	<b>542.0398</b>		
University of Texas Health Science Center at San Antonio		745	60,848.30
			<b>60,848.30</b>
<b>PP120089 - Cancer Genetic Risk Assessment, Counseling, and Screening of High-risk Individuals in Greater San Antonio and South Texas: Education and Implementation</b>	<b>542.0400</b>		



University of Texas Health Science Center at San Antonio	745	38,491.95	
		<b>38,491.95</b>	
<b>RP101382-C03 - Core 3</b>	<b>542.0404</b>		
University of Texas Health Science Center at San Antonio	745	154,723.61	
		<b>154,723.61</b>	
<b>RP110524 - Stromal remodeling, local aromatase induction, and breast cancer risk</b>	<b>542.0405</b>		
University of Texas Health Science Center at San Antonio	745	154,899.77	
		<b>154,899.77</b>	
<b>RP120190 - Oncometabolites in Renal Cancer</b>	<b>542.0406</b>		
University of Texas Health Science Center at San Antonio	745	10,199.95	
		<b>10,199.95</b>	
<b>RP120290 - Targeting hedgehog pathway for prostate cancer treatment</b>	<b>542.0407</b>		
University of Texas Health Science Center at San Antonio	745	127,048.70	
		<b>127,048.70</b>	
<b>RP120372 - A next-generation sequencing strategy to identify chromosomal translocations targeting the immunoglobulin loci in B-cell malignancies</b>	<b>542.0408</b>		
University of Texas Health Science Center at San Antonio	745	9,937.32	
		<b>9,937.32</b>	
<b>RP120462 - Environmental Determinants of Hepatocellular Carcinoma in South Texas</b>	<b>542.0409</b>		
University of Texas Health Science Center at San Antonio	745	76,864.58	
		<b>76,864.58</b>	
<b>PP110190 - Comprehensive breast cancer prevention for high-risk women in Dallas County</b>	<b>542.0415</b>		
University of North Texas Health Science Center at Fort Worth	763	142,013.08	
		<b>142,013.08</b>	
<b>Total Pass-Through to Other Agencies (Exh. II):</b>			<b>65,459,151.92</b>



